146 related articles for article (PubMed ID: 17682201)
1. [Indications and limitations of primary systemic therapy for operable breast cancer].
Yamamoto N; Suzuki M; Tanabe N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():500-6. PubMed ID: 17682201
[No Abstract] [Full Text] [Related]
2. [Primary systemic chemotherapy for breast conserving surgery].
Fukutomi T
Nihon Rinsho; 2007 Jun; 65 Suppl 6():507-10. PubMed ID: 17682202
[No Abstract] [Full Text] [Related]
3. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
4. [Breast conserving surgery after preoperative chemotherapy].
Miyaguni T; Murayama S; Nishimaki T
Nihon Rinsho; 2007 Jun; 65 Suppl 6():445-8. PubMed ID: 17682191
[No Abstract] [Full Text] [Related]
5. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
6. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
7. [So that survival chances in breast cancer are improved. Finding a "clinical trial opportunity" for your patients].
Vetter C
MMW Fortschr Med; 2003 Apr; 145(16):14. PubMed ID: 14606393
[No Abstract] [Full Text] [Related]
8. Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer.
Clavarezza M; Venturini M
Oncology; 2009; 77 Suppl 1():14-7. PubMed ID: 20130427
[TBL] [Abstract][Full Text] [Related]
9. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
10. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
11. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
12. [Optimal chemotherapy for advanced and recurrent breast cancer patients].
Masuda N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():523-9. PubMed ID: 17682205
[No Abstract] [Full Text] [Related]
13. [The development of breast cancer therapy in Germany in 2004].
Haller U; Winter R; Untch M
Gynakol Geburtshilfliche Rundsch; 2004 Apr; 44(2):61-2. PubMed ID: 15067227
[No Abstract] [Full Text] [Related]
14. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Ahluwalia MS; Daw HA
J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
[No Abstract] [Full Text] [Related]
15. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
Baselga J; Smith BL; Rafferty EA; Bombonati A
N Engl J Med; 2012 May; 366(21):2018-26. PubMed ID: 22621630
[No Abstract] [Full Text] [Related]
16. Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial.
Yamaguchi T; Mukai H
Jpn J Clin Oncol; 2012 Dec; 42(12):1211-4. PubMed ID: 23129778
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant systemic therapies in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Surg Clin North Am; 2013 Apr; 93(2):473-91. PubMed ID: 23464697
[TBL] [Abstract][Full Text] [Related]
18. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer].
Xu L; Liu YH; Ye JM; Zhao JX; Duan XN; Zhang LB; Zhang H; Wang YH
Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(6):450-3. PubMed ID: 20627009
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]